Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (21-30 of 204) with videos related to

Pageof 21
Sort By:
American Journal of Respiratory and Critical Care Medicine|March 5, 2013
Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusionsJotam G Pasipanodya, Tawanda Gumbo
The Lancet. Child & Adolescent Health|July 21, 2019
Dosing tuberculosis drugs in young children: the road aheadJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?Jotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
The Relationship Between Drug Concentration in Tuberculosis Lesions, Epithelial Lining Fluid, and Clinical OutcomesJotam G Pasipanodya, Tawanda Gumbo
Current Opinion in Pharmacology|August 3, 2011
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugsJotam G Pasipanodya, Tawanda Gumbo
The Journal of Antimicrobial Chemotherapy|February 5, 2020
Repurposing drugs for treatment of Mycobacterium abscessus: a view to a killTawanda Gumbo, Kayle Cirrincione, Shashikant Srivastava
The Journal of Antimicrobial Chemotherapy|September 20, 2017
A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecastingDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Frontiers in Pharmacology|November 28, 2025
Tigecycline pharmacodynamics in the hollow fiber system of <i>Mycobacterium avium</i>-complex lung disease and the utility of MICs and time-kill studies in drug developmentDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Frontiers in Pharmacology|November 8, 2021
Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant <i>Mycobacterium tuberculosis</i>Shashikant Srivastava, Tawanda Gumbo, Tania Thomas
International Journal of Antimicrobial Agents|May 16, 2024
Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre modelDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Pageof 21

Showing results (21-30 of 204) with videos related to

Sort By:
Pageof 21
American Journal of Respiratory and Critical Care Medicine|March 5, 2013
Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusionsJotam G Pasipanodya, Tawanda Gumbo
The Lancet. Child & Adolescent Health|July 21, 2019
Dosing tuberculosis drugs in young children: the road aheadJotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?Jotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
The Relationship Between Drug Concentration in Tuberculosis Lesions, Epithelial Lining Fluid, and Clinical OutcomesJotam G Pasipanodya, Tawanda Gumbo
Current Opinion in Pharmacology|August 3, 2011
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugsJotam G Pasipanodya, Tawanda Gumbo
The Journal of Antimicrobial Chemotherapy|February 5, 2020
Repurposing drugs for treatment of Mycobacterium abscessus: a view to a killTawanda Gumbo, Kayle Cirrincione, Shashikant Srivastava
The Journal of Antimicrobial Chemotherapy|September 20, 2017
A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecastingDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Frontiers in Pharmacology|November 28, 2025
Tigecycline pharmacodynamics in the hollow fiber system of <i>Mycobacterium avium</i>-complex lung disease and the utility of MICs and time-kill studies in drug developmentDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Frontiers in Pharmacology|November 8, 2021
Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant <i>Mycobacterium tuberculosis</i>Shashikant Srivastava, Tawanda Gumbo, Tania Thomas
International Journal of Antimicrobial Agents|May 16, 2024
Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre modelDevyani Deshpande, Shashikant Srivastava, Tawanda Gumbo
Pageof 21